Your shopping cart is currently empty

GLP-1R agonist 32 (Compound 111) is an orally active and potent GLP-1R agonist with an EC50 value of 0.017 nM. It stimulates the production of cyclic adenosine monophosphate (cAMP) by activating GLP-1R, which enhances insulin secretion, suppresses glucagon release, and delays gastric emptying to regulate blood glucose levels. GLP-1R agonist 32 shows potential for research in type 2 diabetes, obesity, and related metabolic disorders.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | GLP-1R agonist 32 (Compound 111) is an orally active and potent GLP-1R agonist with an EC50 value of 0.017 nM. It stimulates the production of cyclic adenosine monophosphate (cAMP) by activating GLP-1R, which enhances insulin secretion, suppresses glucagon release, and delays gastric emptying to regulate blood glucose levels. GLP-1R agonist 32 shows potential for research in type 2 diabetes, obesity, and related metabolic disorders. |
| Molecular Weight | 592.06 |
| Formula | C32H31ClFN3O5 |
| Cas No. | 3047875-57-7 |
| Smiles | C(N1C=2C(N=C1CN3CCC(CC3)C4=C5C(O[C@@H](CO5)C6=CC=C(Cl)C=C6)=CC=C4)=C(F)C=C(C(O)=O)C2)[C@@H]7CCO7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.